Mansuor A. Alanazi

Dr. Mansuor A. Alanazi

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
MQMona Kamel Eed Qushawy
Mona Kamel Eed Qushawy
MAMansuor A. Alanazi
Mansuor A. Alanazi
WHWafaa M Hikal
Wafaa M Hikal
PAPalanisamy Amirthalingam
Palanisamy Amirthalingam
EAEman Abu-Gharbieh
Eman Abu-Gharbieh
AEAmira M Elsherbini
Amira M Elsherbini
Background: Diabetes is a chronic metabolic disease that causes serious consequences in different organs such as the heart, kidneys, pancreas, and liver. Metformin (MTF) is a common treatment for type 2 diabetes. It controls the blood glucose level by improving insulin sensitivity and glucose absorption. MTF belongs to BCS class III, which is characterized by high solubility and low permeability. Several types of nanoparticles have been developed to overcome the permeability problem of MTF. Methods: In this study, we prepared nanostructured lipid carriers (NLCs) loaded with metformin (MTF) using hot melt homogenization-ultrasonication. To select the best formulation, the prepared MTF-NLCs were evaluated for entrapment efficiency % (EE%), particle size, zeta potential, polydispersity index (PDI), and in vitro drug release. The optimized formulation was selected based on the high EE%, small particle size, high absolute zeta potential, low polydispersity index, and high in vitro drug release. The optimized formulation was evaluated for surface morphology by transmission electron microscope (TEM) and for further biochemical and histological analyses in a high-fat diet-induced type 2 diabetes mellitus (T2DM) in vivo rat model; HFD was administered (44.3-kJ/kg total energy) for four weeks, followed by a single intraperitoneal injection of streptozotocin (STZ). Rats were allocated into four groups; Diabetic (DM), DM+MTF, DM+MTF-NLC, and control group. Serum and tissue samples were processed for inflammatory markers detection and histopathology. Results: The prepared MTF-NLC formulation exhibited high EE% (80.65 ± 1.95% to 99.31 ± 3.25%), small particle size (247.72± 5.74nm-503.23± 7.26nm), high negative zeta potential (from − 31.83‎±‎ 0.98mV to − 51.6‎±‎ 2.64mV), PDI value less than 0.5 for all MTF-NLCs, and controlled drug release. MTF-NLC7 appeared spherical when examined by TEM. MTF and MTF-NLC groups significantly alleviated the degenerative effects of DM in both submandibular glands (SMG) and pancreas. Additionally, treatments improved kidney and liver function reduced serum inflammatory cytokines, and tissue SMG and pancreatic immunostaining of inflammatory cytokines with favorable effects of MTF-NLCs. Moreover, the MTF-NLCs showed a significant reduction of serum inflammatory cytokines, including (TNF-α and IL-1β) and pancreatic TNF-α expression, in addition to ameliorating liver and renal functions compared to MTF alone. Conclusion: The preparation of MTF as NLCs improved its permeability, enhancing its anti-inflammatory activity and providing more protection against diabetes-induced organ injury.

8 January 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
AYAsmaa Mokhtar Yosef
Asmaa Mokhtar Yosef
RARaghad Saleh Alqarni
Raghad Saleh Alqarni
FSFai Yahya Sayd
Fai Yahya Sayd
MAManar Saleem Alhawiti
Manar Saleem Alhawiti
RARaghad M. Almahlawi
Raghad M. Almahlawi
MQMona Kamel Eed Qushawy
Mona Kamel Eed Qushawy
Chitosan succinate is distinguished by its ability to shield the loaded drug from the acidic environment, localize and keep the drug at the colon site, and release the drug over an extended time at basic pH. The current study attempts to develop polyelectrolyte liposomes (PEL), using chitosan and chitosan succinate (CSSC), as a carrier for liposomal-assisted colon target delivery of 5 fluorouracil (5FU). The central composite design was used to obtain an optimized formulation of 5FU-chitosomes. The chitosan-coated liposomes (chitosomes) were prepared by thin lipid film hydration technique. After that, the optimized formulation was coated with CSSC, which has several carboxylic (COOH) groups that produce an anionic charge that interacts with the cation NH2 in chitosan. The prepared 5FU-chitosomes formulations were evaluated for entrapment efficiency % (EE%), particle size, and in vitro drug release. The optimized 5FU-chitosomes formulation was examined for particle size, zeta potential, in vitro release, and mucoadhesive properties in comparison with the equivalent 5FU-liposomes and 5FU-PEL. The prepared 5FU-chitosomes exhibited high EE%, small particle size, low polydispersity index, and prolonged drug release. PEL significantly limited the drug release at acidic pH due to the deprotonation of carboxylate ions in CSSC, which resulted in strong repulsive forces, significant swelling, and prolonged drug release. According to a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay, PEL treatment significantly decreased the viability of HT-29 cells. When compared to 5FU-liposome and 5FU-chitosome, the in vivo pharmacokinetics characteristics of 5FU-PEL significantly (p < 0.05) improved. The findings show that PEL enhances 5FU permeability, which permits high drug concentrations to enter cells and inhibits the growth of colon cancer cells. Based on the current research, PEL may be used as a liposomal-assisted colon-specific delivery.

25 October 2022 in Cureus
Verified
Journal Article
Open access
MAMansuor A. Alanazi
Mansuor A. Alanazi
AAAmirah M M Alatawi
Amirah M M Alatawi
Diabetes Mellitus (DM) types 1 and 2 and their complications are becoming more prevalent in Saudi Arabia. Non-adherence to diabetes management techniques could result in inadequate blood sugar management causing treatment failure, the rapid development of comorbidities, and higher mortality in patients with diabetes. This study investigated the adherence of patients with diabetes in the Tabuk region of Saudi Arabia to their prescribed medications and examined the association between adherence and other sociodemographic characteristics. This cross-sectional study was conducted in Tabuk, Saudi Arabia, among patients with diabetes. A validated online self-administered questionnaire was provided to the research participants using Google Forms. Participants were selected using a convenient non-probability sampling method. The chi-square test was used to compare qualitative data whereas quantitative data were expressed as frequency and percentage. Overall, 380 participants were enrolled in this study. The study population’s average diabetes treatment adherence score was 9.6 ± 3.3% from a maximum score of 15 (range: 0-15). Overall, 293 (77.1%) participants were adherent, whereas 87 (22.9%) were non-adherent. In addition, more than one-third of the individuals did not miss medication doses or follow-up appointments. However, forgetfulness was the most common cause of missed medicine doses and follow-up appointments. In addition, several sociodemographic characteristics, including marital status, nationality, geographic region, and employment position, were significantly associated with DM treatment adherence (P = 0.001, 0.002, 0.003, and 0.002, respectively). Most individuals in Tabuk, Saudi Arabia, showed adequate DM medication adherence. Forgetfulness was the most common cause for missed medicine doses and follow-up appointments while several socioeconomic factors including marital status, nationality, geographic region, and occupation were associated with treatment adherence. Therefore, intervention strategies and public health campaigns should be implemented to increase treatment adherence among patients with DM.

16 January 2026 in Medicine
Verified
Journal Article
Open access
HAHisham Alshadfan
Hisham Alshadfan
HMHyder Mirghani
Hyder Mirghani
TATariq Alrasheed
Tariq Alrasheed
MAMansuor A. Alanazi
Mansuor A. Alanazi
AAAmirah M M Alatawi
Amirah M M Alatawi
MAMuhammad Nazrul Hakim Abdullah
Muhammad Nazrul Hakim Abdullah
Gastrointestinal (GI) side effects from metformin often limit its use and can impact patient quality of life (QoL) and satisfaction. The extended-release (XR) formulation is thought to cause fewer GI adverse events than immediate-release (IR) metformin, potentially improving tolerability, treatment satisfaction, and adherence. To compare metformin IR vs XR in terms of GI tolerability (incidence of GI side effects), patient-reported QoL, and medication satisfaction over 6 months in Saudi patients with type 2 diabetes. In a prospective cohort of 119 newly diagnosed patients with type 2 diabetes (62 on IR, 57 on XR), we tracked GI adverse events using a standardized questionnaire at baseline and 6-month follow-up. Diabetes-specific QoL was measured with the diabetes therapy-related quality of life questionnaire (DTR-QOL), and treatment satisfaction was assessed with the oral hypoglycemic agent questionnaire version 2 (OHA-Q ver. 2). Metformin XR was associated with significantly better GI tolerability. By 6 months, 45.2% of IR patients and only 24.5% of XR patients reported any GI side effect ( P <.05). Rates of bothersome symptoms, such as diarrhea, were notably higher in the IR group. Patients on XR reported fewer interruptions of therapy due to GI upset. The DTR-QOL global score improved in both groups ( P <.05), but there was no significant difference in total DTR-QOL scores between groups ( P = .390). The OHA-Q ver. 2 global score improved in both groups ( P <.05), but the XR group had higher scores in domains related to satisfaction (median treatment satisfaction domain score 100 vs 77.78 for IR, P < .05), with a significant difference in OHA-Q ver. 2 global score (92.59 vs 86.31 for IR; P <.05). Metformin XR demonstrated superior GI tolerability, which translated into improved treatment satisfaction compared to IR. While the overall quality of life related to diabetes management improved similarly with both, the XR formulation reduced side effect burden, and the lower daily dosing led to higher patient-reported satisfaction. These findings support the use of metformin XR to enhance tolerability and adherence, potentially leading to improved long-term outcomes.

25 November 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
AAAli Alghamdi
Ali Alghamdi
MAMansuor A. Alanazi
Mansuor A. Alanazi
SBSalwa Q. Q. Bukhari
Salwa Q. Q. Bukhari
RAReham A. Alsumaira
Reham A. Alsumaira
RARazan H. Alenzi
Razan H. Alenzi
MAMohammed A. Alsheikh
Mohammed A. Alsheikh
Background/Objectives: Type 2 diabetes mellitus (T2DM) is increasingly recognized as a contributor to skeletal fragility despite patients often having a normal or even elevated bone mineral density (BMD), a phenomenon described as the “T2DM bone paradox.” This study aimed to use DEXA screening to explore how metabolic and demographic factors, particularly body mass index (BMI), age, sex, and glycated hemoglobin (HbA1c), influence Bone Mineral Density (BMD) among Saudi adults, a population where diabetes and obesity are highly prevalent. Methods: A retrospective cross-sectional study was conducted among 89 adults (mean age 61.1 years; 82% female) who underwent dual-energy X-ray absorptiometry (DEXA) at King Fahad Specialist Hospital in Tabuk, Saudi Arabia. Bone mineral density was evaluated at the lumbar spine, femoral neck, and total hip. Correlation and multiple regression analyses were conducted to assess how age, sex, body mass index (BMI), and glycated hemoglobin (HbA1c) were related to BMD T-scores. Results: The prevalence of osteopenia and osteoporosis was 43.8% and 23.6%, respectively, with women and older adults showing the highest rates of low bone mass. Participants had a mean age of 61.1 ± 12.1 years, average BMI of 32 kg/m2, and mean HbA1c of 6.6 ± 1.8%. Females showed slightly lower T-scores at all skeletal sites compared with males (lumbar spine −1.81 vs. −1.55; femoral neck −1.15 vs. −0.76; total hip −0.62 vs. −0.12), indicating greater bone loss in women. BMI was consistently and positively associated with BMD across all skeletal sites (p < 0.05), whereas age and female sex were negative predictors at the femoral neck and hip. HbA1c showed a paradoxical positive relationship with BMD at weight-bearing sites, reflecting the complexity of metabolic effects on bone quality. The models explained up to 28% of the variance in BMD. Conclusions: Individuals with higher level BMI tended to have better bone mass, while older age and female sex were related to decreased BMD. The positive association between HbA1c and BMD supports the concept of the “diabetic bone paradox” and emphasizes the value of combining the evaluation of both metabolic and skeletal factors when assessing fracture risk in Middle Eastern populations.

29 March 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VVVidhya Rajalakshmi V
Vidhya Rajalakshmi V
ARAkilandeswari Ramu
Akilandeswari Ramu
JCJayaprakash Chinnappan
Jayaprakash Chinnappan
PVPalanivel Velmurugan
Palanivel Velmurugan
RPRajiv Pathak
Rajiv Pathak
TSThangavelu Sathiamoorthi
Thangavelu Sathiamoorthi
COVID-19 caused by the SARS-CoV-2 virus is widespread in all regions, and it disturbs host immune system functioning leading to extreme inflammatory reaction and hyperactivation of the immune response. Kabasura Kudineer (KSK) is preventive medicine against viral infections and a potent immune booster for inflammation-related diseases. We hypothesize that KSK and KSK similar plant compounds, might prevent or control the COVID-19 infection in the human body. 1,207 KSK and KSK similar compounds were listed and screened via the Swiss ADME tool and PAINS Remover; 303 compounds were filtered including active and similar drug compounds. The targets were retrieved from similar drugs of the active compounds of KSK. Finally, 573 genes were listed after several screening steps. Next, network analysis was performed to finalize the potential target gene: construction of protein-protein interaction of 573 genes using STRING, identifying top hub genes in Cytoscape plug-ins (MCODE and cytoHubba). These ten hub genes play a crucial role in the inflammatory response. Target-miRNA interaction was also constructed using the miRNet tool to interpret miRNAs of the target genes and their functions. Functional annotation was done via DAVID to gain a complete insight into the mechanism of the enriched pathways and other diseases related to the given target genes. In Molecular Docking analysis, IL10 attained top rank in Target-miRNA interaction and also the gene formed prominent exchanges with an excellent binding score (> = -8.0) against 19 compounds. Among them, Guggulsterone has an acute affinity score of -8.8 for IL10 and exhibits anti-inflammatory and immunomodulatory properties. Molecular Dynamics simulation study also performed for IL10 and the interacting ligand compounds using GROMACS. Finally, Guggulsterone will be recommended to enhance immunity against several inflammatory diseases, including COVID19.